Earnings ·
Aligos Therapeutics reports Q3 net loss of $21.9M and cash balance of $31.1M
ALGSAligos Therapeutics, Inc.
Aligos Therapeutics reported a third-quarter 2026 net loss of $21.9 million, or $2.09 per share, compared to a $31.5 million loss in the prior-year period. The company held cash and investments of $31.1 million as of September 30, 2026, which management expects will fund operations into the first quarter of 2027. R&D expenses decreased to $18.9 million from $23.9 million due to lower third-party costs for the pevifoscorvir sodium Phase 2 trial. The company also announced that enrollment is complete in the B-SUPREME study, with topline data expected in late Q3 2027. Aligos Therapeutics is a clinical-stage biotechnology company developing therapies for liver and viral diseases.